Stereotaxis (STXS) Non-Current Deffered Revenue (2010 - 2026)
Stereotaxis (STXS) posted quarterly Non-Current Deffered Revenue of $523000.0 for Q1 2026, down 69.2% year-over-year from $1.7 million in Q1 2025, and down 5.77% quarter-over-quarter from $555000.0 in Q4 2025.
Stereotaxis (STXS) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Non-Current Deffered Revenue for 17 consecutive years, with $523000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 69.2% year-over-year to $523000.0; the TTM figure through Mar 2026 stood at $523000.0 (down 69.2% YoY), while the FY2025 annual figure was $555000.0, down 73.11% from the prior year.
- Non-Current Deffered Revenue declined to $523000.0 in Q1 2026 per STXS's latest filing, from $555000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $2.1 million in Q2 2024 and bottomed at $523000.0 in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $1.5 million across 5 years, with a median of $1.6 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue surged 56.29% — and 2025, when it tumbled 73.11%.
- Stereotaxis' Non-Current Deffered Revenue stood at $1.7 million in 2022, then fell by 1.03% to $1.6 million in 2023, then rose by 26.08% to $2.1 million in 2024, then sank by 73.11% to $555000.0 in 2025, then fell by 5.77% to $523000.0 in 2026.
- Business Quant data shows STXS's Non-Current Deffered Revenue at $523000.0 in Q1 2026, $555000.0 in Q4 2025, and $607000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 170.95 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 13.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 208.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | 523,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 523,000.00 |
| Dec 31, 2025 | 555,000.00 |
| Sep 30, 2025 | 607,000.00 |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.12 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.71 Mn |
| Dec 31, 2022 | 1.65 Mn |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 1.63 Mn |
| Mar 31, 2022 | 2.08 Mn |
| Dec 31, 2021 | 2.24 Mn |
| Sep 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | 1.65 Mn |